PL2734230T3 - Rekombinowana szczepionka przeciwko wirusowi białaczki kotów zawierająca zoptymalizowany gen otoczki wirusa białaczki kotów - Google Patents

Rekombinowana szczepionka przeciwko wirusowi białaczki kotów zawierająca zoptymalizowany gen otoczki wirusa białaczki kotów

Info

Publication number
PL2734230T3
PL2734230T3 PL12705199T PL12705199T PL2734230T3 PL 2734230 T3 PL2734230 T3 PL 2734230T3 PL 12705199 T PL12705199 T PL 12705199T PL 12705199 T PL12705199 T PL 12705199T PL 2734230 T3 PL2734230 T3 PL 2734230T3
Authority
PL
Poland
Prior art keywords
leukemia virus
feline leukemia
vaccine containing
envelope gene
recombinant
Prior art date
Application number
PL12705199T
Other languages
English (en)
Polish (pl)
Inventor
Hervé Poulet
Thierry Heidmann
Original Assignee
Merial Limited
Centre National De La Recherche Scientifique
Institut Gustave Roussy
Université Paris-Sud
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Limited, Centre National De La Recherche Scientifique, Institut Gustave Roussy, Université Paris-Sud filed Critical Merial Limited
Publication of PL2734230T3 publication Critical patent/PL2734230T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/04Nitro compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/21Retroviridae, e.g. equine infectious anemia virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/275Poxviridae, e.g. avipoxvirus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08RNA viruses
    • C07K14/15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5256Virus expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24041Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24041Use of virus, viral particle or viral elements as a vector
    • C12N2710/24044Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/13011Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13022New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/13011Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13034Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00Nucleic acids vectors
    • C12N2800/22Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL12705199T 2011-07-20 2012-02-02 Rekombinowana szczepionka przeciwko wirusowi białaczki kotów zawierająca zoptymalizowany gen otoczki wirusa białaczki kotów PL2734230T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161509912P 2011-07-20 2011-07-20
PCT/US2012/023658 WO2013012446A1 (en) 2011-07-20 2012-02-02 Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
EP12705199.3A EP2734230B1 (en) 2011-07-20 2012-02-02 Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene

Publications (1)

Publication Number Publication Date
PL2734230T3 true PL2734230T3 (pl) 2019-07-31

Family

ID=45722710

Family Applications (1)

Application Number Title Priority Date Filing Date
PL12705199T PL2734230T3 (pl) 2011-07-20 2012-02-02 Rekombinowana szczepionka przeciwko wirusowi białaczki kotów zawierająca zoptymalizowany gen otoczki wirusa białaczki kotów

Country Status (25)

Country Link
US (2) US8895027B2 (cg-RX-API-DMAC7.html)
EP (1) EP2734230B1 (cg-RX-API-DMAC7.html)
JP (2) JP6084970B2 (cg-RX-API-DMAC7.html)
CN (1) CN103957932B (cg-RX-API-DMAC7.html)
AU (2) AU2012284558B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014001287B1 (cg-RX-API-DMAC7.html)
CA (1) CA2842055C (cg-RX-API-DMAC7.html)
CY (1) CY1125328T1 (cg-RX-API-DMAC7.html)
DK (1) DK2734230T3 (cg-RX-API-DMAC7.html)
ES (1) ES2720150T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20190271T1 (cg-RX-API-DMAC7.html)
HU (1) HUE043547T2 (cg-RX-API-DMAC7.html)
IL (1) IL230460B (cg-RX-API-DMAC7.html)
IN (1) IN2014CN00547A (cg-RX-API-DMAC7.html)
LT (1) LT2734230T (cg-RX-API-DMAC7.html)
MX (1) MX351642B (cg-RX-API-DMAC7.html)
PL (1) PL2734230T3 (cg-RX-API-DMAC7.html)
PT (1) PT2734230T (cg-RX-API-DMAC7.html)
RS (1) RS58289B1 (cg-RX-API-DMAC7.html)
RU (1) RU2591817C2 (cg-RX-API-DMAC7.html)
SI (1) SI2734230T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900129T1 (cg-RX-API-DMAC7.html)
TR (1) TR201901466T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013012446A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201400349B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731659A (en) 2014-11-03 2018-10-26 Merial Inc Methods of using microneedle vaccine formulations to elicit in animals protective immunity against rabies virus
EP3691679A2 (en) * 2017-10-06 2020-08-12 Virbac Feline vaccines conferring early protection
CN111848785B (zh) * 2020-07-10 2022-09-06 青岛博隆基因工程有限公司 猫疱疹病毒抗体序列、四肽链分子、免疫球蛋白分子

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
DE3730599A1 (de) 1986-09-12 1988-07-07 Genentech Inc Verfahren zur kontinuierlichen herstellung von heterologen proteinen in eukaryontischen wirtszellen
IL84154A0 (en) 1986-10-16 1988-03-31 Microgenesys Inc Polypeptides derived from the envelope gene of human immunodeficiency virus in recombinant baculovirus infected insect cells and vaccines against acquired immune deficiency syndrome containing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
CA2003300A1 (en) 1988-11-21 1990-05-21 Franklin Volvovitz Skin test and test kit for aids
CA2005311C (en) * 1988-12-13 2006-05-30 Edward A. Hoover Prototype felv isolates for use in disease models and vaccines
DE69233158T2 (de) 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
FR2712603B1 (fr) 1993-11-18 1996-02-09 Centre Nat Rech Scient Virus recombinants, préparation et utilisation en thérapie génique.
US5529780A (en) 1994-03-30 1996-06-25 Virogenetics Corporation Nucleotide and amino acid sequences of canine herpesvirus gB and gC
CA2214029A1 (en) 1995-04-25 1996-10-31 Magda Marquet Single-vial formulations of dna/lipid complexes
EP0803573A1 (en) 1996-04-25 1997-10-29 Gesellschaft für Biotechnologische Forschung mbH (GBF) Polycistronic expression construct with cytokines for multivalent vaccines
US5846946A (en) 1996-06-14 1998-12-08 Pasteur Merieux Serums Et Vaccins Compositions and methods for administering Borrelia DNA
US6090393A (en) 1996-07-03 2000-07-18 Merial Recombinant canine adenoviruses, method for making and uses thereof
WO1998000166A1 (en) 1996-07-03 1998-01-08 Merial, Inc. Recombinant canine adenovirus (cav) containing exogenous dna
US6156567A (en) 1996-07-03 2000-12-05 Merial Truncated transcriptionally active cytomegalovirus promoters
FR2775601B1 (fr) 1998-03-03 2001-09-21 Merial Sas Vaccins vivants recombines et adjuves
FR2776928B1 (fr) 1998-04-03 2000-06-23 Merial Sas Vaccins adn adjuves
TWI224107B (en) 1998-10-22 2004-11-21 Pfizer Prod Inc Novel proteins from actinobacillus pleuropneumoniae
US6017537A (en) 1998-12-18 2000-01-25 Connaught Laboratories, Inc. Formyl methionyl peptide vaccine adjuvant
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines
MXPA02003108A (es) 1999-09-25 2003-10-14 Univ Iowa Res Found Acidos nucleicos inmunoestimuladores.
US6852705B2 (en) 2000-01-21 2005-02-08 Merial DNA vaccines for farm animals, in particular bovines and porcines
EP1203819A3 (en) 2000-10-06 2002-08-07 Transgene S.A. Anti-inflammatory vectors
CN1561389A (zh) * 2001-07-25 2005-01-05 纽约大学 糖基神经酰胺作为用于抗传染病和癌症的疫苗的佐剂的用途
FR2829498B1 (fr) 2001-09-11 2003-11-28 Merial Sas Igf-1 comme adjuvant de vaccin felin, notamment contre les retrovirus felins
AU2002365202A1 (en) 2001-11-09 2003-09-02 Entremed, Inc. Synthetic genes for malarial proteins and methods of use
AU2003245416A1 (en) 2002-06-07 2004-04-30 University Of Florida Endodontic files made using bulk metallic glasses
DE50304603D1 (de) * 2002-09-23 2006-09-21 Mologen Ag Impfstoff gegen infektionen mit onkoviren, wie dem felinen leukosevirus der katze
BRPI0509497B1 (pt) * 2004-03-30 2022-07-19 Institut Gustave Roussy Seqüência de polipeptídeos envolvida na modulação do efeito imunosupressor de proteínas virais
CA2570156C (en) 2004-06-04 2014-09-30 Merial Limited Needle-free administration of felv vaccines
US7998733B2 (en) * 2004-10-05 2011-08-16 Merial Limited Chimeric vectors
CN101312742B (zh) * 2005-09-16 2012-07-25 梅瑞尔有限公司 用于冷冻干燥的疫苗的稳定剂
WO2008150404A1 (en) * 2007-05-30 2008-12-11 Wyeth Raccoon poxvirus expressing genes of feline antigens

Also Published As

Publication number Publication date
HRP20190271T1 (hr) 2019-03-22
US20130022632A1 (en) 2013-01-24
ES2720150T3 (es) 2019-07-18
PT2734230T (pt) 2019-02-27
SMT201900129T1 (it) 2019-05-10
US8895027B2 (en) 2014-11-25
MX351642B (es) 2017-10-23
RU2014106295A (ru) 2015-08-27
ZA201400349B (en) 2015-08-26
JP6240294B2 (ja) 2017-11-29
US20150030623A1 (en) 2015-01-29
IL230460B (en) 2018-11-29
AU2012284558A1 (en) 2014-02-20
EP2734230A1 (en) 2014-05-28
WO2013012446A1 (en) 2013-01-24
RS58289B1 (sr) 2019-03-29
TR201901466T4 (tr) 2019-02-21
EP2734230B1 (en) 2018-11-21
CA2842055A1 (en) 2013-01-24
CN103957932A (zh) 2014-07-30
HUE043547T2 (hu) 2019-08-28
NZ620566A (en) 2016-02-26
IN2014CN00547A (cg-RX-API-DMAC7.html) 2015-04-03
JP2014528699A (ja) 2014-10-30
CY1125328T1 (el) 2023-03-24
IL230460A0 (en) 2014-03-31
BR112014001287B1 (pt) 2020-12-08
AU2017204298A1 (en) 2017-07-13
LT2734230T (lt) 2019-03-25
JP6084970B2 (ja) 2017-02-22
SI2734230T1 (sl) 2019-04-30
DK2734230T3 (en) 2019-01-28
AU2012284558B2 (en) 2017-06-29
RU2591817C2 (ru) 2016-07-20
US9856295B2 (en) 2018-01-02
MX2014000625A (es) 2015-06-02
CA2842055C (en) 2019-04-02
CN103957932B (zh) 2017-06-23
JP2017052774A (ja) 2017-03-16
BR112014001287A2 (pt) 2017-02-21

Similar Documents

Publication Publication Date Title
SG11201400432VA (en) Polypeptide vaccine
SG10201508700XA (en) Recombinant subunit dengue virus vaccine
IL231983A0 (en) Dna containing tricyclo-phosphorothioate
PL2551190T3 (pl) Zmiennopłat
PL2551198T3 (pl) Zmiennopłat
EP2655392A4 (en) CYCLIC NUCLEOTID ANALOGS
EP2678005A4 (en) GLUCOLOPOPEPTIDE MUC1-BASED VACCINE WITH AN ADJUVANS
GB201118636D0 (en) Nucleotide sequence
IL231132A0 (en) Viral cleaning methods
IL231043A0 (en) vaccine
IL222228A0 (en) Hiv vaccine
IL235891A0 (en) Peptides derived from viral proteins for use as immunogens and dose responders
AP2013007180A0 (en) Truncated HIV envelope proteins (ENV), methods andcompositions related thereto
ZA201209260B (en) Novel intergenic elements for enhancing gene expression
IL239152A0 (en) Biological mixture inactivated from viruses
GB201119999D0 (en) Vaccine
ZA201303410B (en) Viral polymerase inhibitors
ZA201400349B (en) Recombinant feline leukemia virus vaccine containing optimized feline leukemia virus envelope gene
GB201004143D0 (en) Promoter sequence for DNA and viral vectors
GB201120109D0 (en) Malaria vaccine
GB2496849B (en) Improved DNA plasmid system
GB201218465D0 (en) Viral infection cofactor
GB201120000D0 (en) Vaccine
EP2663657A4 (en) GENOMIC ASSEMBLY
PL394842A1 (pl) Koperta na korespondencje